Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer

By Hütter G.   Szélenyi H.   Deckert P.   Keilholz U.   Thiel E.  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 2, 2004-08 ,pp. : 178-184

Springer Publishing Company

Access to resources Recommend Favorite

Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients

By Bensmane M.A.   de Gramont A.   Brienza S.   Marty M.   Levi F.   Ducreux M.   Francois E.   Gamelin E.   Bleiberg H.   Bleuzen P.   Simon J.   Cvitkovic E.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2335-2343

Elsevier

Access to resources Recommend Favorite

Short-Time Infusion of Oxaliplatin (Eloxatin®) in Combination with Capecitabine (Xeloda®) in Patients with Advanced Colorectal Cancer

By Pfeiffer Per   Hahn Pernille   Anita Jensen Helle  

Acta Oncologica, Vol. 42, Iss. 8, 2003-12 ,pp. : 832-836

Informa Healthcare

Access to resources Recommend Favorite

DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: Results from genotyping study on 75 gastric carcinoma and colon carcinoma patients

By  

Medical Oncology, Vol. 24, Iss. 2, 2007-06 ,pp. : 251-258

Humana Press, Inc

Access to resources Recommend Favorite

A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary

By Carlson Heather  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 226-231

Springer Publishing Company

Access to resources Recommend Favorite